CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Block & Leviton LLP has launched an investigation into **Corcept Therapeutics Inc. (NASDAQ: CORT)** over possible violations of U.S. securities laws following a dramatic drop in the company’s share price. The firm is urging investors who have lost money in Corcept stock to reach out and learn how they might recover their losses. The stock plunged more than 50% on December 31, 2025, after Corcept revealed it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its drug candidate relacorilant. The letter indicated that the FDA could not determine a favorable risk–benefit profile without further evidence of effectiveness, spooking investors and prompting regulatory scrutiny. Block & Leviton’s probe will assess whether Corcept and its executives may have made misleading statements or failed to disclose material information to the market. Investors who purchased Corcept common stock and suffered losses may be eligible to participate in potential legal action, regardless of whether they have already sold their shares. Those affected are encouraged to contact the firm through its case website, by email at , or by phone at (888) 256‑2510. The firm also notes that individuals with non‑public information about Corcept could assist in the investigation and may be eligible for whistleblower rewards through the U.S. Securities and Exchange Commission. #CorceptTherapeutics #SecuritiesInvestigation #BlockAndLeviton #InvestorAlert #SlimScan #GrowthStocks #CANSLIM